FDA Approval, Gene and Gene Expression - Clinical Research Informer

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

JULY 29, 2022

The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder. In 2013, the US Food and Drug Administration (FDA) approved Ravicti (glycerol phenylbutyrate), manufactured by Hyperion Therapeutics, which has since then been acquired by Horizon Pharma.

RNA

RNA Gene Expression Gene Gene Therapy

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

XTalks

JUNE 17, 2022

Eli Lilly’s Olumiant (baricitinib) has won US Food and Drug Administration (FDA) approval as the first systemic treatment for severe alopecia areata (AA), an autoimmune disorder that leads to patchy baldness. The Olumiant approval is therefore a big win as it helps fulfill a significant unmet need in the area.

FDA Approval

FDA Approval Gene Expression Cosmetics Trials

Data dive finds cheap diuretic could be Alzheimer’s drug

pharmaphorum

OCTOBER 12, 2021

Bumetanide’s potential was discovered by analysing data on more than 1,300 FDA-approved drugs derived from brain tissue samples, laboratory experiments involving animal and human cells, and human population studies.

Gene Expression

Gene Expression Drugs FDA Approval Gene

World Mental Health Day 2023: Drug discovery breakthroughs

Drug Discovery World

OCTOBER 10, 2023

Read more: Another milestone achieved in major depressive disorder trial More accessible treatment The US Food and Drug Administration (FDA) approved Sage Therapeutics’ Zurzuvae (zuranolone) in August, making it the first oral medication indicated to treat postpartum depression (PPD) in adults.

Drugs

Drugs Gene Expression Gene Immune Response

Vtama (tapinarof) Cream Gains FDA Approval for the Treatment of Plaque Psoriasis in Adults

XTalks

MAY 31, 2022

Tapinarof treatment in a mouse model of psoriasis resulted in the downregulation of inflammatory cytokine expression in skin tissue, which involved IL17A , IL17F , IL19 , IL22 , IL23A and IL1B gene expression. Clinical Trials of Vtama.

FDA Approval

FDA Approval Clinical Trials Clinical Trials Trials

AI tool may help doctors select best drugs for COVID patients

pharmaphorum

NOVEMBER 12, 2021

Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients.

Doctors

Doctors Doctor Drugs Gene Expression

Artificial intelligence could be new blueprint for precision drug discovery

The Pharma Data

JULY 12, 2021

online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval. “Academic labs and pharmaceutical and? Nature Communications, 2021.

Drugs

Drugs Gene Expression Big Data Gene

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

JANUARY 14, 2024

Given the ongoing scientific advancements and the rise of FDA-approved biologics, the pharmaceutical industry seems to be approaching the era of biologics. This can be attributed to the fact that the production of biopharmaceuticals requires living expression systems.

Contract Manufacturing

Contract Manufacturing Manufacturing Protein Bacteria

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

Life Science

Life Science Vaccination Vaccine Gene

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

pharmaphorum

OCTOBER 27, 2022

It can be caused by different types of mutation, including within the BRCA gene and other forms of altered gene expression. PARP inhibitors, which are now used as a first-line management in newly diagnosed individuals, include the FDA-approved olaparib, as well as rucaparib and niraparib.

Trials

Trials DNA Genome Genomics

Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation

The Pharma Data

OCTOBER 15, 2020

Immuno-oncology and CAR T cells energized the field of regenerative medicine, but for cell and gene to deliver on their promises, new, disruptive technologies and new modes of operation are needed. As with dry AMD, there is no FDA-approved therapy. “We Other cell and gene companies are advancing solutions, too.

Manufacturing

Manufacturing Gene Therapy Gene Gene Expression

Prominent Reasons Behind The Failure Of NAMPT inhibitors And Key Strategies Adopted By Developers To Overcome Such Challenges

Roots Analysis

NOVEMBER 3, 2023

NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. Further, we identified the key parameters / strategies that, we believe, are likely to have a significant impact on the FDA approval of NAMPT inhibitors.

Development

Development Drugs Trials FDA Approval

Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

The Pharma Data

JANUARY 17, 2021

As a result, there is a high unmet need for an FDA approved local injection therapy that is safe and effective. 1 and COX-2 gene expression. The various forms of surgical modalities carry significant cutaneous adverse events, risk of scar, infection and bleeding. Surgery can also have a significant recurrence rate.

Gene Expression

Gene Expression Trials Production Development

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

AUGUST 12, 2020

Related: FDA Approves Rukobia for HIV Patients with Limited Treatment Options. The results of persistent, underlying HIV infection include heightened immune activation and inflammation (leading to a number of diseases), ongoing damage to multiple organ systems and reduced life expectancy.

RNA

RNA Protein DNA In-Vivo

Clinical Research Informer

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

Trending Sources

Data dive finds cheap diuretic could be Alzheimer’s drug

World Mental Health Day 2023: Drug discovery breakthroughs

Vtama (tapinarof) Cream Gains FDA Approval for the Treatment of Plaque Psoriasis in Adults

AI tool may help doctors select best drugs for COVID patients

Artificial intelligence could be new blueprint for precision drug discovery

Biologics – The Next Step in Revolutionary Medication

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

Disruptive Technologies and Mature Regulatory Environment Vital for Cell Therapy Maturation

Prominent Reasons Behind The Failure Of NAMPT inhibitors And Key Strategies Adopted By Developers To Overcome Such Challenges

Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

What the Glycome Can Tell Us About Persistent HIV Infection

Stay Connected